WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (known outside the United States and Canada as MSD) today provided an update on the development programs for vorapaxar, extended release niacin/laropirprant (MK524A, Tredaptive) and anacetrapib in …
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from …
Merck (NYSE: MRK), known outside the United States and Canada as MSD, today reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious disease, and highlighted scientific data presented by …
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from Phase III studies of VICTRELIS® (boceprevir) 200 mg Capsules, the company’s oral hepatitis C virus (HCV) …
BERLIN--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Phase IIb data for MK-3102, the company’s investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes. MK- …
MINNEAPOLIS--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of …
WHITEHOUSE STATION, N.J.--Today, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced plans to initiate two new clinical trials with MK-5172, its investigational, once-daily, oral HCV NS3/4A protease inhibitor for the …
BOSTON--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced interim results from a Phase II, multi-center, randomized, dose-ranging study (n=332) assessing the safety and antiviral activity of MK-5172, an …
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company’s investigational allergy …
WHITEHOUSE STATION, N.J., July 11, 2012 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today an update on the Phase III trial assessing fracture risk reduction with odanacatib, Merck's investigational cathepsin K (cat …
BOSTON, June 13, 2012 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia …
WHITEHOUSE STATION, N.J., June 5, 2012 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) …
WHITEHOUSE STATION N.J., April 27, 2012 - Merck, known as MSD outside the United States and Canada, today presented Phase I data evaluating the safety and tolerability of its novel, oral β-amyloid precursor protein site cleaving enzyme (BACE) inhibitor, MK …
CHICAGO, March 24, 2012 - Researchers today presented and published results from the TRA-2P ( T hrombin- R eceptor A ntagonist in S econdary P revention of Atherothrombotic Ischemic Events) TIMI 50 study of vorapaxar, Merck's investigational anti- …
Whitehouse Station, NJ, and San Diego, March 15, 2012 - Merck, known outside the United States and Canada as MSD, today announced a collaboration to create the California Institute for Biomedical Research (Calibr), an independent, not-for-profit …
WHITEHOUSE STATION, N.J., March 5, 2012 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the results from a Phase III clinical study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen. The …
WHITEHOUSE STATION, N.J., Feb. 7, 2012 - Merck (NYSE:MRK), known outside the United States and Canada as MSD, today announced the top-line results of the TRA-2P ( T hrombin R eceptor A ntagonist in S econdary P revention of atherothrombotic ischemic events …
WHITEHOUSE STATION, N.J., Feb. 6, 2012 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for suvorexant, the company's investigational orexin receptor antagonist, which, if …
WHITEHOUSE STATION, N.J., Dec. 6, 2011 - Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, today announced the establishment of an Asia Research & Development (R&D) headquarters for innovative drug discovery and …
ORLANDO, Nov. 13, 2011 -- Researchers today presented and published results from TRACER ( T hrombin R eceptor A ntagonist for C linical E vent R eduction in Acute Coronary Syndrome), the first clinical outcomes trial of vorapaxar, the investigational …
02 days 05:39:39
